LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
about
Androgen receptor molecular biology and potential targets in prostate cancerMAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancerA novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapyTumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma.CT-X antigen expression in human breast cancer.The biology of cancer testis antigens: putative function, regulation and therapeutic potentialChallenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Cancer testis antigen and immunotherapy.NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.Clinical and Molecular Spectrum of Liposarcoma.Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.[Association of XAGE-1 gene expression with clinical characteristics of lung cancer].
P2860
Q24602861-2387033A-4A09-4F78-AAEF-2F559A36E4DCQ28478930-8A499E63-712B-4078-9650-E4CE2D29422BQ28709361-63BB1A06-2E91-4BA4-AB09-4191AE6C5B70Q29616128-0728BAD8-95A2-40B7-A07E-9D2ABC7C1C01Q34325790-88656927-2189-4189-B485-02887F2CEDB1Q34503895-BB4D237E-4FA7-4AB0-9488-EFBCDD221BA4Q37276789-1C376794-21F4-4D7C-B80F-CC8FCDC96948Q37849976-29660183-B8A1-4DE6-AD92-64BE8DCE5F7EQ38143201-E2C9B1F1-93A0-4694-863E-48F1E4EBEE87Q38912232-F6F1D1B5-13CE-4780-901B-4BDC9F658909Q39294181-908CC92D-1F8D-4A89-8532-3322784FBABBQ41894814-A24ACD4C-462C-4906-B3C6-05CF97B449DEQ43081527-5F72AA14-8989-4708-998E-DD6E128AB2CDQ47315579-97F81E5C-E40E-4E3D-8A3B-12BED1C9B2CBQ55136811-DF4C86B4-2725-4692-B310-36F9735F0AF5Q55465312-03F69496-BED1-46C2-8DFE-535A70D7A476
P2860
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
LUD 00-009: phase 1 study of i ...... th NY-ESO-1-expressing cancer.
@ast
LUD 00-009: phase 1 study of i ...... th NY-ESO-1-expressing cancer.
@en
LUD 00-009: phase 1 study of i ...... th NY-ESO-1-expressing cancer.
@nl
type
label
LUD 00-009: phase 1 study of i ...... th NY-ESO-1-expressing cancer.
@ast
LUD 00-009: phase 1 study of i ...... th NY-ESO-1-expressing cancer.
@en
LUD 00-009: phase 1 study of i ...... th NY-ESO-1-expressing cancer.
@nl
prefLabel
LUD 00-009: phase 1 study of i ...... th NY-ESO-1-expressing cancer.
@ast
LUD 00-009: phase 1 study of i ...... th NY-ESO-1-expressing cancer.
@en
LUD 00-009: phase 1 study of i ...... th NY-ESO-1-expressing cancer.
@nl
P2093
P2860
P1433
P1476
LUD 00-009: phase 1 study of i ...... ith NY-ESO-1-expressing cancer
@en
P2093
Akin Atmaca
Alexander Knuth
Antje Neumann
Armin Bender
Dirk Jäger
Eckhart Weidmann
Elke Jäger
Eric Hoffman
Julia Karbach
P2860
P577
2007-10-19T00:00:00Z